Nutriband Inc. (NASDAQ: NTRB), a company focused on transdermal pharmaceutical products, has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office aimed at strengthening intellectual property protection for its AVERSA abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology's abuse-deterrent properties. If granted, the patent could extend protection for AVERSA-based products, including AVERSA FENTANYL, through 2046. This development is significant because it could provide Nutriband with a durable competitive advantage in the growing market for abuse-deterrent drug delivery systems, particularly amid the ongoing opioid crisis.
Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse, and accidental exposure involving drugs with abuse potential, including opioids and stimulants. The new application, if approved, would further solidify the company's intellectual property estate and potentially delay generic competition for its lead product candidate. For investors, this move signals a strategic effort to maximize the commercial lifespan of AVERSA, which is being developed as a key differentiator in the transdermal patch market.
The AVERSA technology is designed to be incorporated into any transdermal patch to deter abuse, misuse, diversion, and accidental exposure. Nutriband's lead product under development is an abuse-deterrent fentanyl patch that utilizes this technology. The company's website is www.nutriband.com, where additional information about its pipeline can be found. However, any material contained in or derived from the company's websites or any other website is not part of this press release.
The patent application's potential to extend protection through 2046 is particularly important given the increasing regulatory and public pressure to address opioid abuse. By securing long-term exclusivity, Nutriband could attract partnership interest from larger pharmaceutical companies seeking to add abuse-deterrent formulations to their portfolios. Moreover, the global scope of Nutriband's existing patents—covering 46 countries—demonstrates a comprehensive approach to protecting its innovation in key markets.
Investors and industry observers can access the full press release at https://ibn.fm/Osmxh. For ongoing news and updates about Nutriband, the company's newsroom is available at https://ibn.fm/NTRB. These resources provide timely information that can help stakeholders assess the company's progress.
MissionIR, a specialized communications platform, distributed this announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which offers a range of services including wire distribution through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. This broad reach helps ensure that news like Nutriband's patent filing reaches a wide audience of investors and industry participants.
In summary, Nutriband's patent application represents a critical step in extending the market exclusivity of its AVERSA technology, potentially safeguarding its position in the abuse-deterrent transdermal space until 2046. This could enhance shareholder value and support the company's efforts to address the opioid epidemic with innovative solutions.
